Inactive Instrument
Antibe Therapeutics Inc. Stock
Stocks
ATE
CA0370255097
Biotechnology & Medical Research
OTC Markets Traded| 04/07/24 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24/04/24 | Antibe Announces Appointment of Receiver | BU |
| 22/04/24 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 19/04/24 | Antibe Provides Update on CCAA Proceedings | BU |
| 17/04/24 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 01/12/2015 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 08/03/24 | Option | Chief Technology Officer | 16,666 | 0.0317% | ||
| 08/03/24 | Option | Chief Technology Officer | 9,000 | 0.0171% | ||
| 08/03/24 | Option | Chief Executive Officer | 35,000 | 0.0665% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +59.46% | - | - | 11.47M | |
| -0.62% | -1.87% | +42.87% | +64.15% | 63.77B | |
| +0.35% | +3.20% | +14.40% | +81.76% | 56.37B | |
| +0.53% | +1.96% | +16.24% | +103.35% | 54.62B | |
| -2.81% | -4.31% | +23.50% | +47.83% | 44.06B | |
| -0.33% | -1.93% | +19.28% | +98.80% | 42.11B | |
| +0.55% | +2.31% | +225.14% | +866.21% | 41B | |
| +3.27% | +47.96% | +112.84% | +96.58% | 34.92B | |
| +1.22% | -1.44% | +14.57% | +46.95% | 32.82B | |
| +0.89% | +20.55% | -40.62% | +349.24% | 24.7B | |
| Average | +0.31% | +7.54% | +47.58% | +194.99% | 43.82B | |
| Weighted average by Cap. | +0.18% | +5.44% | +47.99% | +176.67% |
Employees
11
